BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 27078988)

  • 1. [Modified Shengma Biejia Decoction Combined with CAG Program for Elderly Acute Myeloid Leuke- mia Patients with Yin Deficiency Toxin Stasis Syndrome].
    Dai XB; Sun XM; Jiang PJ; Ni HW; Chen JY; Zhang WX
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Feb; 36(2):149-54. PubMed ID: 27078988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy.
    Zhu HH; Jiang H; Jiang B; Lu J; Jiang Q; Bao L; Zhang XH; Qin YZ; Huang XJ
    Leuk Lymphoma; 2013 Nov; 54(11):2452-7. PubMed ID: 23432721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus idarubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia.
    Jin J; Chen J; Suo S; Qian W; Meng H; Mai W; Tong H; Huang J; Yu W; Wei J; Lou Y
    Leuk Lymphoma; 2015 Jun; 56(6):1691-7. PubMed ID: 25257348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Erdi Biejia decoction for erectile dysfunction with kidney-yin deficiency].
    Huang J; Xu FS
    Zhonghua Nan Ke Xue; 2012 Dec; 18(12):1143-6. PubMed ID: 23405800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical observation on treatment of acute myelocytic leukemia by supplementing qi, nourishing yin and clearing heat principle].
    Xu RR; Cao F; Liu ZX
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 May; 24(5):411-4. PubMed ID: 15199624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy and safety of venetoclax combined with azacitidine versus CAG regimen combined with decitabine in elderly patients with relapsed acute myeloid leukemia].
    Wang P; Zhang LW; Lu CQ; Wang TZ; Shan M; Xiao JY; Tian H; Ma X; Xu Y; Wu DP
    Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):157-163. PubMed ID: 35090250
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of efficacy of HCAG and CAG re-induction chemotherapy in elderly low- and intermediate-risk group patients diagnosed with acute myeloid leukemia.
    Zhang JY; Li L; Liu W; Jin Y; Zhao M; Zhou Y; Fan Z
    Clin Transl Oncol; 2021 Jan; 23(1):48-57. PubMed ID: 32458310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
    Qu Q; Liu L; Zhang Y; Li X; Wu D
    Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical efficacy of the patients of acute myeloid leukemia and myelodysplastic syndromes treated with decitabine alone, combined with half or one couse of CAG regimen].
    Gao S; Qiu H; Jin Z; Tang X; Fu Z; Ma X; Han Y; Chen S; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):961-5. PubMed ID: 25417868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of Curative Effects of HAG and CAG Regimens for Patients with AML and Medium/High-Risk MDS].
    Zhu YN; Yang XF; Wang DZ; Liu ZW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):698-701. PubMed ID: 27342493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficiency of benazepril combined with wind dispelling and dampness removing chinese herbs on stage 3 chronic kidney disease with wind-dampness syndrome: a prospective study].
    Fang YQ; Lu Y; Wang YJ
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Mar; 32(3):311-6. PubMed ID: 22686073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing aclarubicin dose in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) is efficacious as salvage chemotherapy for relapsed/refractory mixed-phenotype acute leukemia.
    Liu L; Qu Q; Jiao W; Zhang Y; Li X; Ding C; Wu D
    Leuk Res; 2015 Aug; 39(8):805-11. PubMed ID: 26021434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor priming (CAG regimen) on the outcome of elderly patients with acute myeloid leukemia.
    Qian SX; Li JY; Tian T; Shen YF; Jiang YQ; Lu H; Wu HX; Zhang SJ; Xu W
    Leuk Res; 2007 Oct; 31(10):1383-8. PubMed ID: 17420048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The comparative study of the effects between modified FLAG and CAG on relapsed or refractory acute myeloid leukemia].
    Wang T; Ma L; Zhu Q; Gong R; Gao Z; Tian W
    Zhonghua Xue Ye Xue Za Zhi; 2014 Nov; 35(11):966-9. PubMed ID: 25417870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia: A propensity score analysis.
    Minakata D; Fujiwara S; Ito S; Mashima K; Umino K; Nakano H; Kawasaki Y; Sugimoto M; Yamasaki R; Yamamoto C; Ashizawa M; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Leuk Res; 2016 Mar; 42():82-7. PubMed ID: 26790727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic effect of priming induction regimen of CAG for newly diagnosed acute myeloid leukemia in elderly patients].
    Chen YJ; Zhang LQ; Li XL; Zhao XL; Wu DS; Shu YG; Chen FP
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Mar; 33(3):245-51. PubMed ID: 18382060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multicentered, randomized, controlled clinical trial on patients with IgA nephropathy of Qi-yin deficiency syndrome type].
    Chen XM; Chen YP; Chen J
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2007 Feb; 27(2):101-5. PubMed ID: 17342992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and Safety of Decitabine Combined with CAG (Cytarabine, Aclarubicin, G-CSF) for Patients with Intermediate or High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia: a Meta-Analysis].
    Zhang JL; Cao YP; Li JG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Apr; 27(2):494-503. PubMed ID: 30998160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.